# Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

> **NCT07684144** · PHASE3 · RECRUITING · sponsor: **Amgen** · enrollment: 950 (estimated)

## Conditions studied

- Obesity
- Overweight
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Maridebart Cafraglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07684144
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-29
- **Primary completion:** 2027-12-26
- **Final completion:** 2028-03-19
- **Target enrollment:** 950 (ESTIMATED)
- **Last updated:** 2026-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07684144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07684144, "Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07684144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*